{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:15:20Z","timestamp":1772151320815,"version":"3.50.1"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.2169\/internalmedicine.5233-24","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T22:09:26Z","timestamp":1771106966000},"page":"569-572","source":"Crossref","is-referenced-by-count":1,"title":["Acquired Pure Red Cell Aplasia Following BNT162b2 mRNA COVID-19 Vaccination"],"prefix":"10.2169","volume":"65","author":[{"given":"Naoki","family":"Hayase","sequence":"first","affiliation":[{"name":"Department of Hematology, Takayama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Takayama Red Cross Hospital, Japan"},{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Fukuno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Takayama Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Infectious Disease, Gifu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nakazawa H, Sakai K, Ohta A, et al. Incidence of acquired pure red cell aplasia: a nationwide epidemiologic analysis with 2 registry databases in Japan. Blood Adv 6: 6282-6290, 2022.","DOI":"10.1182\/bloodadvances.2021006486"},{"key":"2","unstructured":"2. Ishida F, Nakazawa H, Harigae H, et al. [A clinical reference and guide on pure red cell aplasia, Reiwa 4 Ed.] [Internet]. [cited 2024 Apr 1]. Available from: https:\/\/zoketsushogaihan.umin.jp\/file\/2022\/pure_red_cell_aplasia.pdf (in Japanese)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yamazaki S, Naito E, Sekiya R, et al. Pure red cell aplasia accompanied by COVID-19 successfully treated using cyclosporine. J Infect Chemother 28: 304-307, 2022.","DOI":"10.1016\/j.jiac.2021.10.018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kimura H, Furukawa M, Shiga Y, et al. Exacerbation of autoimmune hemolytic anemia associated with pure red cell aplasia after COVID-19: a case report. J Infect Chemother 29: 787-791, 2023.","DOI":"10.1016\/j.jiac.2023.04.002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tabata S, Hosoi H, Murata S, Takeda S, Mushino T, Sonoki T. Severe aplastic anemia after COVID-19 mRNA vaccination: causality or coincidence? J Autoimmun 126: 102782, 2022.","DOI":"10.1016\/j.jaut.2021.102782"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jackson EM, Harper S, Webb GJ, Thomas W. Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab. BMJ Case Rep 15: e250774, 2022.","DOI":"10.1136\/bcr-2022-250774"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Koilpillai S, Dominguez B, Khan A, Carlan S. Severe case of refractory immune thrombocytopenic purpura requiring splenectomy after the COVID-19 vaccine. BMJ Case Rep 15: e250153, 2022.","DOI":"10.1136\/bcr-2022-250153"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Waqar SHB, Khan AA, Memon S. Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine. Int J Hematol 114: 626-629, 2021.","DOI":"10.1007\/s12185-021-03190-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vadal\u00e0 M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8: 295-311, 2017.","DOI":"10.1007\/s13167-017-0101-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Boettler T, Csernalabics B, Sali\u00e9 H, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol 77: 653-659, 2022.","DOI":"10.1016\/j.jhep.2022.03.040"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Means RT Jr. Pure red cell aplasia. Blood 128: 2504-2509, 2016.","DOI":"10.1182\/blood-2016-05-717140"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 44: 431-432, 1991.","DOI":"10.1136\/jcp.44.5.431"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Park S, Merlat A, Guesnu M, et al. Pure red cell aplasia associated with myelodysplastic syndromes. Leukemia 14: 1709-1710, 2000.","DOI":"10.1038\/sj.leu.2401833"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wang H, Niu H, Zhang T, Xing L, Shao Z, Fu R. Low- and intermediate-risk myelodysplastic syndrome with pure red cell aplasia. Hematology 26: 444-446, 2021.","DOI":"10.1080\/16078454.2021.1929694"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Korde N, Zhang Y, Loeliger K, et al. Monoclonal gammopathy-associated pure red cell aplasia. Br J Haematol 173: 876-883, 2016.","DOI":"10.1111\/bjh.14012"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Xu LH, Fang JP, Weng WJ, et al. Pure red cell aplasia associated with cytomegalovirus and Epstein-Barr virus infection in seven cases of Chinese children. Hematology 18: 56-59, 2013.","DOI":"10.1179\/1607845412Y.0000000044"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5233-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:43:13Z","timestamp":1771645393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/4\/65_5233-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5233-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"article-number":"5233-24"}}